The investment will allow for the expansion of analytical R&D efforts and will support the company’s reference materials business.
MilliporeSigma plans to build a new, $20-million laboratory facility in Buchs, Switzerland, to support its rapidly growing reference materials business, the company announced in a July 15, 2020 press release. The company anticipates that about two dozen jobs will be created with this expansion.
The three-story, 12,000-ft2 Buchs building is scheduled to be done by December 2021, and the move to the facility is planned for early 2022. The facility will include laboratory and office space aimed at fostering a collaborative environment. The new facility will offer a more efficient working environment for current and future employees in R&D, analytical production, and quality control. The laboratory area can be adapted to new requirements in the future, including increased site capacity.
"Researchers in testing labs around the world use MilliporeSigma’s reference materials every day to help generate accurate, reliable analytical results in pharmaceutical, environmental, and food and beverage analysis,” said Jean-Charles Wirth, head of Applied Solutions at MilliporeSigma, in the company press release. “This new laboratory will allow us to continue to drive innovation in diagnostics and testing and expand our research and development of analytical standards.”
Source: MilliporeSigma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.